Fig. 7: Low doses CAR33-KLRC1ko-NK cells in an OCI-AML2-xenograft NSG-SGM3 mouse model show improved efficacy compared to KLRC1ko-NK or CAR33-NK cells.
a Scheme of the in vivo evaluation of a triple injection treatment with CAR33-KLRC1ko-NK cells (three doses with 5 × 106 cells intravenously) together with a subcutaneous treatment with IL-2 in OCI-AML2 (Luc+) xenograft NSG-SGM3 mouse model. b BLI images of differently treated OCI-AML2 (Luc+) engrafted NSG-SGM3 mice over time (n = 4–9). Mice received three doses of 5 × 106 NK cells on day 3, day 7 and day 10 post-AML cell injection. c Total flux analysis (photons/second) mice (n = 4–9). Mean ± SD. d Survival and leukemic burden of OCI-AML2 engrafted mice was observed over 36 days. e Scheme of the in vivo evaluation of a double injection treatment with CAR33-KLRC1ko-NK cells (two doses with 3 × 106 cells intravenously) together with a subcutaneous treatment with IL-2 in OCI-AML2 (Luc+) xenograft NSG-SGM3 mouse model. f BLI images of differently treated OCI-AML2 (Luc+) engrafted NSG-SGM3 mice over time (n = 3–4). Mice received two doses of 3 × 106 NK cells on day 3 and day 10 post-AML cell injection. g Total flux analysis (photons/s) mice (n = 3–4). Mean ± SD. h Scheme of in vivo bone marrow (BM) re-engraftment experiment. BM cells of NK treated animals (previously untreated (UT), non-transduced (NT)-NK, KLRC1ko-NK, CAR33-NK and CAR33-KLRC1ko-NK treated animals) were isolated at day 18, pooled, and injected into new NSG-SGM3 mice (5 × 106 cells/animal; n = 2–6). i Survival and leukemic burden of BM re-engrafted mice was observed over 120 days (animal protocol: endpoint of the experiment). j Representative confocal microscopy analysis of GFP+ AML cells in BM histology d18 post-AML cell injection. Statistical analysis was performed two-way ANOVA (c, g) and Kaplan–Meier (Log-rank (Mantel–Cox) test) (d, i).
